Setting occupational exposure limits for unstudied pharmaceutical intermediates using an in vitro parallelogram approach

Toxicology Mechanisms and Methods

Volumn 21, Issue 2, 2011, Pages 76-85

  Maier, Mark S V ^a  

^a Cambrex Corporation   (United States)

Author keywords

API; containment; control; ergonomics; exposure; hazard; occupational; OEB; OEL; parallelogram; pharmaceutical; potent compound; risk assessment

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENT; AFLATOXIN; ANTINEOPLASTIC AGENT; AZOXY DERIVATIVE; BETA CYCLODEXTRIN; CEPHALOSPORIN; CHEMICAL AGENT; CYCLODEXTRIN; DOCETAXEL; NITROSO DERIVATIVE; OPIATE; PACLITAXEL; PENICILLIN G; SPIRAMYCIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; BIOLOGICAL ACTIVITY; BONE MARROW SUPPRESSION; CARCINOGENICITY; CELL VIABILITY; COLONY FORMING UNIT; CULTURE MEDIUM; DOSE RESPONSE; ERGONOMICS; ERYTHROID CELL; FLUOROMETRY; GRANULOCYTE; HUMAN; IN VITRO STUDY; MACROPHAGE; MONOCYTE; NEUTROPENIA; OCCUPATIONAL EXPOSURE; OCCUPATIONAL EXPOSURE LIMIT; OCCUPATIONAL HAZARD; PRIORITY JOURNAL; RISK ASSESSMENT; TOXICITY TESTING; TOXICOLOGICAL PARAMETERS; TOXICOLOGY;

ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INDUSTRY; HUMANS; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT;

APIS;

EID: 79551703293     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376511003638280     Document Type: Article

References (25)

1. Collins FS, Gray GM, Bucher JR. 2008. Toxicology. Transforming environmental health protection. Science 319:906-907. (Pubitemid 351263750)
2. Constant S, Huang S, Derouette J, Wiszniewski L. 2008. MucilAir: a novel in vitro human 3D airway epithelium model for assessing the potential hazard of nanoparticles and chemical compounds. Toxicol Lett 180:S233.
3. Dolan DG, Naumann BD, Sargent EV, Maier A, Dourson ML. 2005. Application of the threshold of toxicological concern concept to pharmaceutical manufacturing operations. Regul Toxicol Pharmacol 43:1-9. (Pubitemid 41265868)
4. Dourson ML, Stara JF. 1983. Regulatory history and experimental support of uncertainty (safety) factors. Regul Toxicol Pharmacol 3:224-238. (Pubitemid 14229334)
5. Fleming SL, Jansen CW, Hasson SM. 1997. Effect of glove and type of muscle action on grip fatigue. Ergonomics 40:601-612. (Pubitemid 27237091)
6. Hansson SO. 1998. Setting the limit: Occupational health standards and the limits of science. New York: Oxford University Press.
7. Hasan MA, Lange CF. 2007. Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics. J Aerosol Med 20:282-293. (Pubitemid 47469675)
8. Jarvis J, Seed MJ, Elton R, Sawyer L, Agius R. 2005. Relationship between chemical structure and the occupational asthma hazard of low molecular weight organic compounds. Occup Environ Med 62:243-250.
9. Kavlock RJ, Austin CP, Tice RR. 2009. Toxicity testing in the 21st century: implications for human health risk assessment. Risk Anal 29:485-487.
10. Kroes R, Renwick AG, Cheeseman M, Kleiner J, Mangelsdorf I, Piersma A, Schilter B, Schlatter J, van Schothorst F, Vos JG, Wurtzen G. 2004. Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food Chem Toxicol 42:65-83. (Pubitemid 37421327)
11. Lancaster MV, Fields RD. 1996. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents. US patent: 5501959.
12. Lehman AJ, Fitzhugh OG. 1954.100-Fold margin of safety. Assoc Food Drug Off US Q Bull 18:33-35.
13. Maier MS, Legare ME, Hanneman WH. 2007. The aryl hydrocarbon receptor agonist 3,3′,4,4′,5-pentachlorobiphenyl induces distinct patterns of gene expression between hepatoma and glioma cells: chromatin remodeling as a mechanism for selective effects. Neurotoxicology 28:594-612. (Pubitemid 46850763)
14. Matilainen L, Toropainen T, Vihola H, Hirvonen J, Jarvinen T, Jarho P, Jarvinen K. 2008. In vitro toxicity and permeation of cyclodextrins in Calu-3 cells. J Contr Rel 126:10-16.
15. Naumann BD, Sargent EV, Starkman BS, Fraser WJ, Becker GT, Kirk GD. 1996. Performance-based exposure control limits for pharmaceutical active ingredients. Am Ind Hyg Assoc J 57:33-42.
16. Naumann BD, Weideman PA. 1995. Scientific basis for uncertainty factors used to establish occupational exposure limits for active pharmaceutical ingredients. Hum Ecol Risk Assess 1:590-613.
17. Page B, Page M, Noel C. 1993. A new fluorometric assay for cytotoxicity measurements in vitro. Int J Oncol 3:473-476. (Pubitemid 23271916)
18. Pessina A, Albella B, Bayo M, Bueren J, Brantom P, Casati S, Croera C, Gagliardi G, Foti P, Parchment R, Parent-Massin D, Schoeters G, Sibiril Y, Van Den H, Gribaldo L. 2003. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol Sci 75:355-367. (Pubitemid 37220283)
19. Pessina A, Bonomi A. 2007. CFU-GM assay for evaluation of drug myelotoxic activity. Curr Protoc Toxicol 34(Suppl. 35):20.2.1-20.2.18.
20. Steele RE, Handler JS, Preston A, Johnson JP. 1992. A device for sterile Measurement of transepithelial electrical parameters of cultured cells. J Tiss Cult Meth 14:259-264.
21. UK Health and Safety Executive (UKHSE). 2001. Asthmagen? Critical assessments of the evidence for agents implicated in occupational asthma. Available online at: www.hse.gov.uk/asthma/, accessed September 2009.
22. UK Health and Safety Executive (UKHSE). 2009. Ergonomics in the pharmaceutical industry: identifying occupational health hazards and finding ergonomic solutions. Available online at: www.hse.gov.uk/pharmaceutical/, accessed September 2009.
23. US Environmental Protection Agency (USEPA). 2002. A review of the reference dose and reference concentration process. EPA/630/P-02/002F. Prepared for the Risk Assessment Forum. Washington, DC: USEPA.
24. US Occupational Safety and Health Administration (OSHA). 2005. Nonmandatory compliance guidelines for hazard assessment and personal protective equipment selection. Code of Federal Regulations, Title 29, Pt. 1910, sub. I, app. B.
25. Wani M, Taylor H, Wall M, Coggon P, McPhail A. 1971. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325-2327.